
SWITZERLAND – HBM BioVentures to apply for a listing on the SWX
Venture capital company HBM BioVentures Ltd plans to expand its shareholder base through an IPO. The company intends to issue a limited number of new shares and list all shares on the SWX Swiss Exchange shortly. HBM BioVentures invests globally in emerging companies in the biotechnology and medical technology sectors. The investment focus is emerging private and small-cap public companies that are at varying stages of development. The portfolio includes private companies (59%), public companies originating from the private portfolio (17%), other public companies (11%) and other current assets (13%, including cash of 8%) at this time. It is well diversified in terms of geography, therapeutic areas, the portfolio companies' stage of development and the timing of investments.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds